

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

Lancet 2010; 376: 1670–81

DOI:10.1016/S0140-6736(10)61350-5


Second CTT cycle: more vs less intensive statin therapy

Study	Treatment comparison	N	Target population	Entry lipid criteria
PROVE-IT	A 80 vs. P 40	4162	ACS	TC $\leq$ 240 mg/dL
A to Z	S 40 then S 80 vs. placebo then S 20	4497	ACS	TC $\leq$ 250 mg/dL
TNT	A 80 vs. A 10	10,001	Prior CHD	LDL-C 130-250 mg/dL TG $\leq$ 600 mg/dL
IDEAL	A 80 vs. S 20-40	8888	Prior CHD	TG $\leq$ 600 mg/dL
SEARCH	S 80 vs. S 20	12,064	Prior CHD	TC $\geq$ 4.5 mmol/L or $\geq$ 3.5 if on statins


Second CTT cycle: additional trials of statin vs control

Study	Treatment comparison	N	Target population	Entry lipid criteria
MEGA	P 10-20 vs. usual care	8214	Primary prevention	TC 220-270 mg/dL
JUPITER	R 20 vs. placebo	17 802	Primary prevention (but CRP>2 mg/dL)	LDL-C <130 mg/dL, TG <500 mg/dL
4D	A 20 vs. placebo	1255	Type 2 DM + haemodialysis	LDL-C 80-190 mg/dL TG <1000 mg/dL
AURORA	R 10 vs. placebo	2773	Haemodialysis	None
ALLIANCE	A 10-80 (until LDL <80 mg/dL) vs. usual care	2442	Prior CHD	LDL-C 110-200 mg/dL on lipid lowering drugs, 130-250 mg/dL if not
ASPEN	A 10 vs. placebo	2410	Type 2 DM + CHD or risk factors	LDL-C <150, TG ≤445 mg/dL with CHD; LDL-C <159, TG ≤600 mg/dL without
GISSI-HF	R 10 vs. placebo	4574	CHF	None


Proportional effects on MAJOR VASCULAR EVENTS unweighted for 1-year LDL-C differences




MORE VS LESS STATIN – Proportional effects on MAJOR VASCULAR EVENTS unweighted for 1-year LDL-C differences




Proportional effects on MAJOR VASCULAR EVENTS per mmol/L LDL-C reduction




MORE VS LESS STATIN – Proportional effects on MAJOR VASCULAR EVENTS per mmol/L LDL-C reduction




STATIN VS CONTROL – Proportional effects on MAJOR VASCULAR EVENTS per mmol/L LDL-C reduction




Proportional effects on MAJOR VASCULAR EVENTS per mmol/L LDL-C reduction, by baseline prognostic factors




Proportional effects on MAJOR VASCULAR EVENTS per mmol/L LDL-C reduction, by baseline prognostic factors



Proportional effects on MAJOR VASCULAR EVENTS per mmol/L LDL-C reduction, by baseline LDL-C



Proportional effects on CAUSE-SPECIFIC MORTALITY per mmol/L LDL-C reduction



Proportional effects on SITE SPECIFIC CANCER per mmol/L LDL-C reduction

